Sverre E Kjeldsen

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 32

Top Topics

Peripheral Artery Disease

Top Venues

Hypertension (Dallas, Tex. : 1979)

American journal of hypertension

Current medical research and opinion

This page only lists publications with an associated author ORCID identifier.

Publications

Fadl Elmula M Fadl Elmula, Julian Eek Mariampillai, Sondre Heimark, Sverre E Kjeldsen, Michel Burnier
Medical Measures in Hypertensives Considered Resistant. American journal of hypertension 37 (5) (2024)
Giuseppe Mancia, Mattias Brunström, Michel Burnier, Guido Grassi, Andrzej Januszewicz, Sverre E Kjeldsen, Maria Lorenza Muiesan, Costas Thomopoulos, Konstantinos P Tsioufis, Reinhold Kreutz
Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines. Hypertension (Dallas, Tex. : 1979) 81 (5) (2024)
Giuseppe Mancia, Mattias Brunström, Michel Burnier, Guido Grassi, Andrzej Januszewicz, Sverre E Kjeldsen, Maria Lorenza Muiesan, Costas Thomopoulos, Konstantinos P Tsioufis, Reinhold Kreutz
Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines. Hypertension (Dallas, Tex. : 1979) 81 (5) (2024)
Giuseppe Mancia, Mattias Brunström, Michel Burnier, Guido Grassi, Andrzej Januszewicz, Sverre E Kjeldsen, Maria Lorenza Muiesan, Costas Thomopoulos, Konstantinos P Tsioufis, Reinhold Kreutz
Rationale of the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines. Hypertension (Dallas, Tex. : 1979) (2024)
Sverre E Kjeldsen, Brent M Egan, Michel Burnier, Alistair S Hall, Reinhold Kreutz, Giuseppe Mancia
Highlights of the 2023 European Society of Hypertension Guidelines: what has changed in the management of hypertension in patients with cardiac diseases? Blood pressure 33 (1) (2024)
Sverre E Kjeldsen, Guido Grassi
The role of β-blockers in medical treatment. Current medical research and opinion 40 (sup1) (2024)
Fadl Elmula M Fadl Elmula, Julian Eek Mariampillai, Sondre Heimark, Sverre E Kjeldsen, Michel Burnier
Medical Measures in Hypertensives Considered Resistant. American journal of hypertension 37 (5) (2024)
Fadl Elmula M Fadl Elmula, Julian Eek Mariampillai, Sondre Heimark, Sverre E Kjeldsen, Michel Burnier
Medical Measures in Hypertensives Considered Resistant. American journal of hypertension 37 (5) (2024)
Sverre E Kjeldsen, Guido Grassi
The role of β-blockers in medical treatment. Current medical research and opinion 40 (sup1) (2024)
Mislav Vrsalović, Sondre Heimark, Camilla Lund Søraas, Maria H Mehlum, Sverre E Kjeldsen, Giuseppe Mancia, Stevo Julius, Michael A Weber
Cardiovascular Outcomes in Hypertension-Treated Patients With Peripheral Artery Disease: The VALUE Trial. Hypertension (Dallas, Tex. : 1979) (2024)
Reinhold Kreutz, Mattias Brunström, Sverre E Kjeldsen, Alistair S Hall, Brent M Egan, Michel Burnier
Lowering of systolic blood pressure in hypertensive patients: insights and questions from the ESPRIT study. Blood pressure 33 (1) (2024)
Fadl Elmula M Fadl Elmula, Julian Eek Mariampillai, Sondre Heimark, Sverre E Kjeldsen, Michel Burnier
Medical Measures in Hypertensives Considered Resistant. American journal of hypertension 37 (5) (2024)
Sverre E Kjeldsen, Guido Grassi
The role of β-blockers in medical treatment. Current medical research and opinion 40 (sup1) (2024)
Mislav Vrsalović, Sondre Heimark, Camilla Lund Søraas, Maria H Mehlum, Sverre E Kjeldsen, Giuseppe Mancia, Stevo Julius, Michael A Weber
Cardiovascular Outcomes in Hypertension-Treated Patients With Peripheral Artery Disease: The VALUE Trial. Hypertension (Dallas, Tex. : 1979) 81 (7) (2024)
Giuseppe Mancia, Mattias Brunström, Michel Burnier, Guido Grassi, Andrzej Januszewicz, Sverre E Kjeldsen, Maria Lorenza Muiesan, Costas Thomopoulos, Konstantinos P Tsioufis, Reinhold Kreutz
Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines. Hypertension (Dallas, Tex. : 1979) 81 (5) (2024)
Giuseppe Mancia, Mattias Brunström, Michel Burnier, Guido Grassi, Andrzej Januszewicz, Sverre E Kjeldsen, Maria Lorenza Muiesan, Costas Thomopoulos, Konstantinos P Tsioufis, Reinhold Kreutz
Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines. Hypertension (Dallas, Tex. : 1979) 81 (5) (2024)
Sverre E Kjeldsen, Brent M Egan, Michel Burnier, Alistair S Hall, Reinhold Kreutz, Giuseppe Mancia
Highlights of the 2023 European Society of Hypertension Guidelines: what has changed in the management of hypertension in patients with cardiac diseases? Blood pressure 33 (1) (2024)
Mislav Vrsalović, Sondre Heimark, Camilla Lund Søraas, Maria H Mehlum, Sverre E Kjeldsen, Giuseppe Mancia, Stevo Julius, Michael A Weber
Cardiovascular Outcomes in Hypertension-Treated Patients With Peripheral Artery Disease: The VALUE Trial. Hypertension (Dallas, Tex. : 1979) 81 (7) (2024)
Fadl Elmula M Fadl Elmula, Julian Eek Mariampillai, Sondre Heimark, Sverre E Kjeldsen, Michel Burnier
Medical Measures in Hypertensives Considered Resistant. American journal of hypertension 37 (5) (2024)
Michel Burnier, Jana Brguljan-Hitij, Engi Abd Elhady Algharably, Sverre E Kjeldsen, Alistair S Hall, Brent M Egan, Suzanne Oparil, Reinhold Kreutz
Women's health, cardiovascular risk and hypertension: the perspective still needs to improve. Blood pressure 32 (1) (2023)
Giuseppe Mancia, Sverre E Kjeldsen
Randomized Clinical Outcome Trials in Hypertension. Hypertension (Dallas, Tex. : 1979) (2023)
Sondre Heimark, Maria H Mehlum, Giuseppe Mancia, Camilla L Søraas, Knut Liestøl, Kristian Wachtell, Anne C Larstorp, Morten Rostrup, Julian Eek Mariampillai, Sverre E Kjeldsen, Stevo Julius, Michael A Weber
Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm Hg. Hypertension (Dallas, Tex. : 1979) (2023)
Sverre E Kjeldsen, Brent M Egan, Krzysztof Narkiewicz, Reinhold Kreutz, Michel Burnier, Suzanne Oparil
Thirty years with LIFE-a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy. Blood pressure 31 (1) (2022)
Brent M Egan, Sverre E Kjeldsen, Alistair S Hall, Reinhold Kreutz, Michel Burnier
Single-pill combinations, hypertension control and clinical outcomes: potential, pitfalls and solutions. Blood pressure 31 (1) (2022)
Murray D Esler, Sverre E Kjeldsen, Atul Pathak, Guido Grassi, Reinhold Kreutz, Giuseppe Mancia
Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified. Blood pressure 31 (1) (2022)
Giuseppe Mancia, Sverre E Kjeldsen, Reinhold Kreutz, Atul Pathak, Guido Grassi, Murray D Esler
Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension (Dallas, Tex. : 1979) 79 (6) (2022)
Lene V Halvorsen, Ola U Bergland, Camilla L Søraas, Anne Cecilie K Larstorp, Ulla Hjørnholm, Vibeke N Kjær, Marianne Kristiansen Kringen, Per-Erik Clasen, Renate Haldsrud, Sverre E Kjeldsen, Morten Rostrup, Fadl Elmula M Fadl Elmula, Mimi S Opdal, Aud Høieggen
Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7-Year Follow-Up of Patients Considered Adherent by Directly Observed Therapy. Journal of the American Heart Association 11 (18) (2022)
Sverre E Kjeldsen, Brent M Egan, Alistair S Hall, Reinhold Kreutz, Michel Burnier, Suzanne Oparil, Giuseppe Mancia
TIME to face the reality about evening dosing of antihypertensive drugs in hypertension. Blood pressure 32 (1) (2022)
Ragnhild Sørum Falk, Julian Eek Mariampillai, Erik Edvard Prestgaard, Trond Heir, Johan Bodegard, Trude Eid Robsahm, Irene Grundvold, Per Torger Skretteberg, Kristian Engeseth, Jorgen Vildershoj Bjornholt, Knut Stavem, Knut Liestøl, Leiv Sandvik, Erik Thaulow, Gunnar Erikssen, Sverre E Kjeldsen, Knut Gjesdal, Jan E Erikssen
The Oslo Ischaemia Study: cohort profile. BMJ open 11 (10) (2021)
Eirik Olsen, Björn Holzhauer, Stevo Julius, Sverre E Kjeldsen, Anne Cecilie K Larstorp, Giuseppe Mancia, Maria H Mehlum, Rune Mo, Morten Rostrup, Camilla L Søraas, Dion Zappe, Michael A Weber
Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension. Blood pressure 30 (2) (2021)
Eirik Olsen, Björn Holzhauer, Stevo Julius, Sverre E Kjeldsen, Anne Cecilie K Larstorp, Giuseppe Mancia, Maria H Mehlum, Rune Mo, Morten Rostrup, Camilla L Søraas, Dion Zappe, Michael A Weber
Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk. Blood pressure 30 (2) (2021)
Sverre E Kjeldsen, Ingrid Os
Assessing hypertension therapies: randomization or confounding by indication? Nature reviews. Cardiology 17 (2) (2020)